Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Balsalazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 5/20 | 0.97 |
| ▸ | NME4 | O00746 | 3/20 | 0.97 |
| ▸ | GCDH | Q92947 | 3/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.97 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.97 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.97 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.97 |
| ▸ | HTR3A | P46098 | 1/20 | 0.97 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | BLVRB | P30043 | 2/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Balsalazide SCHEMBL7908058 | 1.00 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL28818120 | 1.00 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL133200 | 0.99 | SIRT5 (0.95) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL29377041 | 0.99 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL3267109 | 0.99 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL118300 | 0.99 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL138311 | 0.99 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL5598491 | 0.97 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL20184744 | 0.92 | SIRT5 (0.87) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL17392780 | 0.92 | SIRT5 (0.87) | SIRT5NME4GCDHTDP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-2096912-B1 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES | SALIX PHARMACEUTICALS INC (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2563117-B1 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES FOR THE TREATMENT OF MALES | SALIX PHARMACEUTICALS LTD (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170333458-A1 | PREVENTION, TREATMENT, AND AMELIORATION OF RADIATION INDUCED ENTERITIS | TECHNOLAS PERFECT VISION GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| US-20160120886-A1 | PREVENTION, TREATMENT, AND AMELIORATION OF RADIATION INDUCED ENTERITIS | Salix Pharmaceuticals, Ltd | 2016-05-05 | — | — | US | disclosed |
| US-9192616-B2 | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives | SALIX PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150132381-A1 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES FOR THE TREATMENT OF MALES | Salix Pharmaceuticals, Ltd (US) | 2015-05-14 | — | — | US | disclosed |
| US-8921344-B2 | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives | SALIX PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130295178-A1 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES FOR THE TREATMENT OF MALES | BAUSCH HEALTH US, LLC | 2013-11-07 | — | — | US | disclosed |
| US-20080306029-A1 | Prevention, Treatment, and Amelioration of Radiation Induced Enteritis | SALIX PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-7452872-B2 | Administering balsalazide with food increases bioavailability of balsalazide and metabolites 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid; label on container recommends to take drug with food; inflammatory bowel disease, radiation enteritis, colon cancer; gastrointestinal disorders | SALIX PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| WO-2008063211-A2 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES | SALIX PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080096849-A1 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES | SALIX PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070265232-A1 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES | SALIX PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1737436-A4 | PREVENTION, TREATMENT, AND AMELIORATION OF RADIATION INDUCED ENTERITIS | SALIX PHARMACEUTICALS INC (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070167416-A1 | Administering 5-aminosalicylate (balsalazide) with food increases bioavailability; label on container recommends to take drug with food; inflammatory bowel disease, radiation enteritis, colon cancer; gastrointestinal disorders | BAUSCH HEALTH US, LLC | 2007-07-19 | — | — | US | disclosed |
| US-20070060552-A1 | Methods and compositions employing 4-aminophenylacetic acid compounds | NOBEX CORPORATION | 2007-03-15 | — | — | US | disclosed |
| EP-1737436-A1 | PREVENTION, TREATMENT, AND AMELIORATION OF RADIATION INDUCED ENTERITIS | Salix Pharmaceuticals, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005117851-A1 | PREVENTION, TREATMENT, AND AMELIORATION OF RADIATION INDUCED ENTERITIS | SALIX PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060552-A1 | Methods and compositions employing 4-aminophenylacetic acid compounds | PGA5, AADAT, ALPI | PTGS1 114/4885PTGS2 105/4885SIRT5 2911/4885 |
| US-20070167416-A1 | Administering 5-aminosalicylate (balsalazide) with food increases bioavailability; label on container recommends to take drug with food; inflammatory bowel disease, radiation enteritis, colon cancer; gastrointestinal disorders | IL5, CYP3A5, APC | PTGS1 501/4885PTGS2 373/4885SIRT5 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.